Kodiak Sciences Inc.
NASDAQ:KODBiotechnology
-$0.03 today
- Market cap
- $6.40B
- Beta
- 2.21
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$3.73
Volume 0.74M
Average 1.10M
KOD Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Kodiak Sciences Inc.NASDAQ: KOD
Accounts Payables · Q3 FY2026 · quarter ended Sep 2026
Accounts payables declines year over year
Q3 FY2026 accounts payables of $4.15M fell 22.0% year over year, behind the -14.9% change in trailing-twelve-month accounts payables. Sequentially, it rose 322.4% from the prior quarter. Over 3 fiscal years it compounded at +69.4% a year.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -22.0% toward the trailing-twelve-month pace of -14.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 8.07M USD
- Year-over-year change
- +183.3%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.07M | +183.3% |
| FY2024 | 2024-12-31 | (9.69M) | -273.2% |
| FY2023 | 2023-12-31 | 5.6M | +237.2% |
| FY2022 | 2022-12-31 | 1.66M | +179.3% |
| FY2021 | 2021-12-31 | (2.09M) | — |
Accounts Payables vs competitors
How KOD compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -14.9% is the 5th highest of 8, against a peer median of +28.5%.
- Over three fiscal years its annual growth of +69.4% compares with a peer median of +10.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.33B USD | +216.1% | — | 8.6% | |
| LTM Jun 2026 | $33.86M USD | -44.5% | -17.0% | 0.6% | |
| LTM Mar 2026 | $10.54M USD | +15832.8% | — | 11.9% | |
| LTM Sep 2026 | $6.02M USD | -14.9% | +69.4% | — | |
| LTM Mar 2026 | $4.9M USD | +28.5% | +8.8% | 1472.1% | |
| LTM Mar 2026 | $2.83M USD | +241.0% | +12.6% | 5.4% | |
| LTM Mar 2026 | CHF 1.63M CHF | -62.8% | — | 323.1% | |
| LTM Mar 2026 | $274K USD | -97.7% | +57.5% | 3.6% | |
BLTEBelite Bio, Inc | LTM Jun 2026 | $0 USD | — | — | — |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding KOD) | — | +28.5% | +10.7% | 7.0% | |
Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (266.99M) | (333.82M) | (260.49M) | (176.21M) | (229.97M) |
| Depreciation & Amortization | 8.71M | 11M | 25.95M | 26.71M | 26.32M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 61.39M | 106.03M | 88.56M | 60.21M | 58.86M |
| Change in Working Capital | 14.43M | 11.96M | (7.36M) | (28.39M) | 6.85M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.09M) | 1.66M | 5.6M | (9.69M) | 8.07M |
| Other Working Capital | 16.52M | 10.3M | (12.95M) | (18.69M) | (1.22M) |
| Other Non-Cash Items | 198K | (1.63M) | (840K) | 355K | 1.93M |
| Operating Cash Flow | (182.27M) | (206.46M) | (154.18M) | (117.32M) | (136.01M) |
| Capital Expenditures | (63.3M) | (47.36M) | (41.43M) | (400K) | (506K) |
| Acquisitions (Net) | 0 | 0 | (290.65K) | 0 | 0 |
| Purchases of Investments | 0 | (427.77M) | (49.35M) | (355K) | 0 |
| Sales of Investments | 24.5M | 138M | 340M | 0 | 0 |
| Other Investing Activities | 0 | 616K | 290.65K | 0 | 0 |
| Investing Cash Flow | (38.8M) | (336.51M) | 249.23M | (755K) | (506K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 8.23M | 1.94M | 242K | 501K | 178.3M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (45K) | (49K) | (211K) | 0 | 0 |
| Financing Cash Flow | 8.18M | 1.9M | 31K | 501K | 178.3M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (212.89M) | (541.08M) | 95.07M | (117.57M) | 41.79M |
| Free Cash Flow | (245.57M) | (253.82M) | (195.61M) | (117.72M) | (136.51M) |
Kodiak Sciences Inc.
NASDAQ:KOD
Intrinsic Alpha fair value
Locked
Current Price
$97.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.